Compare GEO & AVDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GEO | AVDL |
|---|---|---|
| Founded | 1984 | 2015 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.1B |
| IPO Year | 1994 | 1996 |
| Metric | GEO | AVDL |
|---|---|---|
| Price | $17.22 | $21.34 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $41.00 | $18.38 |
| AVG Volume (30 Days) | 1.9M | ★ 2.8M |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 515.49 | N/A |
| EPS | ★ 1.69 | N/A |
| Revenue | ★ $2,531,574,000.00 | $248,517,000.00 |
| Revenue This Year | $7.93 | $65.47 |
| Revenue Next Year | $15.02 | $30.88 |
| P/E Ratio | $10.14 | ★ N/A |
| Revenue Growth | 4.43 | ★ 79.88 |
| 52 Week Low | $14.27 | $6.38 |
| 52 Week High | $36.46 | $23.57 |
| Indicator | GEO | AVDL |
|---|---|---|
| Relative Strength Index (RSI) | 62.45 | 59.01 |
| Support Level | $15.47 | $21.32 |
| Resistance Level | $15.91 | $21.62 |
| Average True Range (ATR) | 0.54 | 0.34 |
| MACD | 0.38 | -0.31 |
| Stochastic Oscillator | 93.62 | 6.90 |
The GEO Group Inc specializes in detention facilities and community reentry centers. It operates in four segments: U.S. Secure Services, which mainly encompasses U.S.-based secure services business; Electronic Monitoring and Supervision Services, which conducts its services in the United States, represents services provided to adults for monitoring services and evidence-based supervision and treatment programs for community-based parolees, probationers, and pretrial defendants; Reentry Services conducts its services in the United States represents services provided to adults for residential and non-residential treatment, educational and community-based programs, pre-release and half-way house programs; and International Services.
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.